References
- US Preventive Services Task Force. Screening for prostate cancer: recommendation and rationale. Ann Intern Med 2002;137(11): 915–6
- Gronberg H. Prostate cancer epidemiology. Lancet 2003;361(9360): 859–64
- Young JM, Muscatello DJ, Ward JE. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int 2000;85(9): 1037–48
- Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000;283(22): 2975–8
- Lu-Yao G, Albertsen PC, Stanford JL, et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325(7367): 740–5
- Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003: 53(1): 5–26
- Concato J, Wells CK, Penson D, et al. Effectiveness of screening for prostate cancer: a nested case-control study. (Abstr) J Clin Epidemiol 2002; 55:627–32
- Boer R, Schroder FH. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. (Letter) Prostate 1999;40(2): 130–1
- Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: Does practice reflect the evidence? JAMA 2003;289(11): 1414–20
- Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancer—part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999;91 (12): 1033–9
- Mettlin C, Littrup PJ, Kane RA, et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age- referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project. Cancer 1994; 74(5): 1615–20
- Hoffman RM, Clanon DL, Littenberg B, et al. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med 2000; 15(10): 739–48
- Partin MR, Wilt TJ. Informing patients about prostate cancer screening: identifying and meeting the challenges while the evidence remains uncertain. Am J Med 2002; 113(8): 691–3
- Welch HG. Informed choice in cancer screening. JAMA 2001;285(21): 2776–8
- Schapira MM, VanRuiswyk J. The effect of an illustrated pamphlet decision-aid on the use of prostate cancer screening tests. J Fam Pract 2000; 49(5): 418–24
- Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11): 781–9
- Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347(11): 790–6
- Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Huntingt) 1997;11(8): 1133–9